Background: Donor lung thrombus are considered a significant etiology for primary graft dysfunction (PGD). We hypothesized that thrombolysis in an ex vivo lung perfusion (EVLP) before lung transplantation could alleviate ischemia-reperfusion injury (IRI), resulting in the reduction of primary graft dysfunction.
Introduction
The preservation and evaluation of donor organs using normothermic ex vivo lung perfusion (EVLP) before transplantation represents a new and active frontier in lung transplantation. [1] [2] [3] In addition to preservation and evaluation, reconditioning of the marginal lungs is also being investigated. [4] [5] [6] [7] [8] In previous work, we focused on the thrombi formation in donor lungs, considered to be among the major causes of primary graft dysfunction 9, 10 and demonstrated that direct fibrinolytic agent (plasmin) administration to the EVLP perfusate could recondition the graft function. 8 Although we showed that plasmin administration during EVLP could be protect lungs damaged by thrombus, the effects after reperfusion are still unclear. Unlike under in vivo condition, the perfusate used in acellular EVLP does not contain white blood cells, red blood cells, platelets, and so on. At the time of reperfusion, reactive oxygen species and cytokines produced in the ischemic period are known to activate neutrophils and platelets contained in the recipient's blood, resulting in ischemia-reperfusion-induced vascular damages and lung edema. 11, 12 Thus, under in vivo condition, donor lungs might be severely damaged by white blood cells and platelets after reperfusion.
The aim of this study was to ascertain the effect of plasmin administration in EVLP against ischemia reperfusion injury in donor lungs in more clinically simulated settings. We also investigated that the physiologic data at the end of EVLP could predict the functions of the donor lungs after reperfusion.
Methods

Animals
Male Lewis rats (Japan SLC, Hamamatsu, Japan) were used in this study. All animals received All rats were randomly assigned to one of the following three groups: heart-beating donor (control; n = 5), untreated thrombosis (non-plasmin; n = 7), or treated thrombosis (plasmin; n = 7). The body weight of the rats was similar in all three of these groups.
Heart-lung bloc preparation
Rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg), intubated after tracheotomy, and ventilated during surgery. In the non-plasmin and plasmin groups, rats did not receive heparin and underwent warm ischemia after occlusion of their airways for 120 minute at 23°C.
After 120 minutes of warm ischemia, the pulmonary artery and left atrium were directly cannulated.
The lungs were flushed with 20 ml of Steen solution (Vitrolife, Uppsala, Sweden) (temperature 4°C; pressure 20 cm H 2 O), with drainage through an incision of the left ventricle. After flushing period, a cannula was inserted into the left atrium. The pulmonary artery cannula and left ventricle cannula were connected to the perfusion circuit. Low-flow perfusion (1 mL/min) with Steen solution was initiated. Finaly, the heart and lungs were excised en bloc.
EVLP model
To evaluate lung function, we used the isolated rat lung perfusion setup (Model 829; Hugo-Sachs Electronik Harvard Apparatus, Holliston, MA). The isolated heart-lung bloc was secured in an artificial thorax and ventilated with ambient air at negative pressure under the conditions as previously described. 8 The lungs were perfused with Steen solution. EVLP was started at a low flow (1 ml/min) rate, and the flow rate was gradually increased every 2 minutes in a stepwise manner (1→ 3→5→7→10 ml/min). Pulmonary arterial pressure was limited carefully so that lungs in each group did not develop edema during this step-up period. Heparin was not added to the perfusate to allow clear evaluation of the fibrinolytic ability of plasmin. At the initiation of the EVLP period, 0.5 mg human plasmin (Catalog No. HCPM-0140; Hematologic Technologies, Inc., Essex Junction, VT), diluted with 0.5 ml of Steen solution, was administered from the origin of the pulmonary artery in the plasmin group. In the same manner, 0.5 ml of Steen solution was administered to the non-plasmin group. Assessment of the isolated lungs began after 10 minutes of the step-up period and lasted for 30 minutes. PaO 2 of the perfusate was analyzed just after the step-up period and at the end of EVLP period. Fibrin/fibrinogen degradation products (FDP) in the perfusate were analyzed 10 minutes after injection of plasmin or placebo (SRL, Tokyo, Japan). Pulmonary vascular resistance (PVR; in cm H 2 O/mL · min, defined as pulmonary arterial pressure-pulmonary vein pressure/perfusate flow), weight gain of the lung (mg), and dynamic airway compliance (ml/cm H 2 O), were monitored continuously and recorded at 10-minute intervals during EVLP. Physiologic data from each group were continuously recorded and analyzed after the experiment.
In the non-plasmin and plasmin groups, the lungs were detached from EVLP system, inflated with air, covered with gauze dampened by cold steen solusion and stored at 4°C for 90 minutes.
Reperfusion model
In the plasmin and non-plasmin groups, lungs were reperfused for 80 minutes at 37°C using an isolated rat lung perfusion model in which physiologic lung function was evaluated. The solution used in the reperfusion model contained heparinized rat blood obtained from two donor rats and saline with 4% albumin. The hematocrit was adjusted to approximately 15%, and the pH was adjusted to 7.25-7.35 with sodium bicarbonate. The lungs were reperfused with low flow (1 ml/min) and the flow rate was gradually increased every 2 minutes, (1→3→5→7→10 ml/min) and ventilated with the same condition used in the EVLP experiment ( Figure 1 ).
Histologic analysis
After reperfusion, the right lower lobe was retrieved and fixed using 10% formalin to evaluate the damage during reperfusion. Single-strand DNA (ssDNA) staining using hematoxylin and eosin (H&E) stain was performed in each group.
Caspase activity assay
Caspase-3 and -7 activity in lung tissue was measured using a Caspase-Glo assay kit (Promega, Madson, WI). Left lungs were stored at −80°C after 80 minutes of reperfusion. The lung tissue was homogenized with homogenizer beads at 4°C in hypotonic extraction buffer and subsequently centrifuged. The protein concentration of the supernatant was adjusted to 1 mg/ml with extraction buffer and stored at −80°C. Proluminescent substrate contained in the Caspase-Glo TM Reagent (Promega) was cleaved by caspase-3, caspase-7. After caspase cleavage, a substrate for luciferase was released, resulting in the production of a luminescent signal. The luminescence of each sample was measured in a plate-reading luminometer.
Statistical analysis
All statistical analyses were performed using StatView 5.0 software (Abacus Concepts, Berkeley, CA, USA). All values are presented as mean ± standard error of the mean (SEM). Data were evaluated using repeated-measures analysis of variance, Scheffe's post hoc multiple comparison test, and Student's paired t-test. A probability p < 0.05 was considered statistically significant.
Results
Fibrinolytic ability of plasmin
FDP levels in the perfusate 10 minutes after administration of plasmin or placebo (Steen solution) are presented in Figure 2 . The levels in the perfusate 10 minutes after injection were higher in the plasmin group than in the non-plasmin group (non-plasmin group: 175.9 ± 31.3 ng, plasmin group: 805.9 ± 202.9 ng, p = 0.0097).
Pulmonary function during EVLP and reperfusion
Pulmonary vascular resistance (PVR)
The PVR in the plasmin group was significantly lower than that in the non-plasmin group during EVLP. (non-plasmin vs plasmin, p = 0.0062 at 30 min; Figure 3a ). PVR in the non-plasmin group during reperfusion was significantly higher than that in the plasmin and control groups (control vs non-plasmin: p = 0.0128, non-plasmin vs plasmin: p = 0.021, plasmin vs control: p = 0.862, Figure   4a ).
Weight gain
In this model, weight gain reflects pulmonary edema. Although the weight gain of the heart-lung bloc increased and was higher in the non-plasmin group than in the plasmin groups (p = 0.001 at 30 minutes; Figure 3b ), not all lungs in the non-plasmin group developed lung edema during the EVLP period. In contrast, weight gain of the heart-lung bloc significantly increased in the non-plasmin group than in the plasmin and control groups during the reperfusion period (control vs non-plasmin: p = 0.002, non-plasmin vs plasmin: p = 0.0007, plasmin vs control: p = 0.862; Figure 4b ).
Dynamic compliance
Dynamic compliance during EVLP was slightly lower in the non-plasmin group than in the plasmin group (p = 0.010 at 30 minutes; Figure 3c ). In contrast, dynamic compliance during reperfusion was significantly lower in the non-plasmin group than in the plasmin group (control vs non-plasmin: p < 0.0001, non-plasmin vs plasmin: p = 0.0001, plasmin vs control: p = 0.0006 at 80 min; Figure 4c ).
PaO 2
PaO 2 in the plasmin and non-plasmin group was not high but was significantly lower in the non-plasmin group than in the plasmin group during EVLP (p = 0.021 at 30 minutes; Figure 4d ). In contrast, PaO 2 in the plasmin group was significantly higher than that in the non-plasmin group during reperfusion (control vs non-plasmin: p < 0.0001, non-plasmin vs plasmin: p < 0.0001, plasmin vs control: p = 0.0002 at 80 minutes; Figure 4d ).
Correlation of physiological data between EVLP and reperfusion in the plasmin and non-plasmin groups
PVR at the end of EVLP significantly correlated with that at 80 minutes after reperfusion (r = 0.66, p = 0.011, Figure 5a ). Lung oxygenation at the end of EVLP slightly correlated with that at 80 minutes after reperfusion (r = 0.56, p = 0.036; Figure 5c ). However, there was no significant correlation between the dynamic pulmonary compliance at the end of EVLP and that at 80 minutes after reperfusion (r = 0.48, p = 0.085; Figure 5c ).
Histologic findings after reperfusion
Lungs in the non-plasmin group exhibited stronger edema and hemorrhage than those in the plasmin group. H&E stain showed significant alveolar edema and accumulation of red blood cells in pulmonary vascular and alveolar tissue, particularly in the peripheral zone ( Figure 6 ). ssDNA staining showed significantly fewer apoptosis cells in the plasmin group than in the non-plasmin group ( Figure   6 ).
Caspase-3 and -7 activity assay
Caspase activity reflect early stages of apoptosis. Caspase activity of the lungs in each group was higher in the non-plasmin and plasmin group than in the control group. Caspase -3 and -7 activity in the plasmin group was lower than that in the non-plasmin group. (control: 4.1 × 10 5 , non-plasmin: 12.8 × 10 5 , plasmin: 6.5 × 10 5 , control vs non-plasmin: p < 0.0001, non-plasmin vs plasmin: p < 0.0001, plasmin vs control: p = 0.030). There was a twofold increase in caspase 3/7 activity (Figure 7) in the control group compared with the activity in the plasmin group (p < 0.0001).
Discussion
Thrombus formation in donor grafts is recognized as one of the most significant factors in primary graft dysfunction. 9, 10 Several studies have shown the possibility for fibrinolytic treatment of damaged donor grafts. [13] [14] [15] [16] [17] Plasminogen activator was used in these studies as a fibrinolytic agent. However, to recondition and evaluate the donor graft in ex vivo lung perfusion, direct fibrinolytic agents should be used because the perfusate in EVLP does not contain plasminogen. This is why we used plasmin as a fibrinolytic agent in this study. Using plasmin in EVLP has three advantages. First, plasmin can lyse fibrin without plasminogen. 18 19 Second, plasmin is not inactivated in EVLP because alpha-2 antiplasmin is not contained in EVLP perfusate. 20 Third, the risk of bleeding after reperfusion is low because plasmin is inactivated immediately by alpha-2 antiplasmin even if residual plasmin exists in the donor lung after EVLP. 20 As such, plasmin is tailored for ex vivo reconditioning of donor lungs damaged by thrombus. We have reported the efficacy of plasmin administration to the EVLP perfusate. 8 However, the physiological data after reperfusion is still unclear. It is known that ischemia induces macrophages and endothelial cells to produce reactive oxygen species, cytokines, nicotinamide adenine dinucleotide phosphate oxidase and cell adhesion molecules. 11 12 Activation of neutrophils and upregulation of cell adhesion molecules on endothelial cells induce neutrophils to transmigrate into the inflammatory sites. 21 , 22 In addition, Platelet activation is induced after reperfusion. These sequential changes increase PVR and pulmonary capillary permeability, resulting in lung edema after reperfusion. 11 12 The perfusate in EVLP does not contain white blood cells, platelets and red blood cells; therefore, evaluation in EVLP could differ from that after reperfusion. To simulate the clinical settings of lung transplantation, the lung was stored at 4°C for 90 minutes after warm ischemia and reperfused with rat blood for 80 minutes. Unlike our previous study, plasmin was administered during low perfusion flow because we believed that plasmin is effective administered rather in low flow than high flow. Furthermore, to prevent vascular damage, it may be important to add plasmin as early as possible. In this study, during EVLP, the difference in physiological data between the plasmin and non-plasmin groups was not very large; however, almost all data after reperfusion were significantly different between these two groups. The histological findings in the non-plasmin group showed severe edema and alveolar hemorrhage. We could find many apoptotic cells with ssDNA staining and the results of caspase activity assay corresponded with these findings.
Interestingly, the peripheral area where we find large amount of residual thrombus after EVLP in our previous study, was severely damaged after reperfusion. At first, we considered that thrombus in the lung reduce the vascular bed and increase vascular pressure, which causes lung edema in normal area.
However, the findings in this study strongly suggested that the peripheral lung area whose pulmonary artery was obstructed by thrombus was latently damaged by insufficient perfusion during EVLP in the non-plasmin group. However the area normally perfused was not severely damaged, which showed a small difference in the physiological data between the groups. After reperfusion, thrombus in the donor lung was resolved by plasminogen in the blood and the malperfusion areas were reperfused.
Then, after reperfusion, severe damage was strongly induced by the inflow of white blood cells and platelets in this area, which resulted in a significant difference in the variety of data between the groups .
Of note is that we observed a correlation between the physiological data at the end of EVLP and that at the end of reperfusion in this study. This precious data might give roads to the possibility that we can predict the behavior of the lung after reperfusion by physiological data during EVLP. In fact, PVR at the end of EVLP showed a significant correlation with that at the end of reperfusion, which means that PVR would be a useful parameter to detect the damage by thrombus and to evaluate the effect of fibrinolytic treatment. Although there was also a slight correlation between PaO 2 at the end of EVLP and that at 80 minutes after EVLP, the range of PaO 2 was very narrow. Because acellular solution contains no erythrocytes, the solution is saturated immediately, even in the edematous condition.
Therefore, acellular EVLP cannot detect the difference in PaO 2 between the two groups. As Yeung et al also demonstrated that PaO 2 cannot detect lung damage with acellular solution. 23 We also consider that PaO 2 is not a useful parameter to predict lung function after reperfusion. Dynamic compliance is considered to be one of the most sensitive parameters to evaluate the lungs in EVLP. 23 Although dynamic compliance at the end of EVLP tended to correlate with that at 80 minutes after reperfusion, it was not significant in this study. However, the compliance after reperfusion was worse than that expected by the compliance during EVLP. As described above, after reperfusion, malperfused areas were damaged by white blood cells after reperfusion, resulting in severe edema and alveolar hemorrhage in the non-plasmin group.
There are several limitations to our study. First, to produce thrombus in the donor lungs, we used a model including 120 minutes of warm ischemia without heparinization, which represents a longer warm ischemic time than the clinical scenario of uncontrolled donation after cardiac death. A thrombosis model without dispersion is difficult to design, whereas the method used here is a simple way to initiate thrombosis in a donor lung. Another limitation with the model used here is that the lungs were ventilated with negative pressure during the EVLP period, whereas, in the clinical setting, positive ventilation is used.
In conclusion, in this clinically simulated study, our results confirmed that plasmin administration during EVLP could recondition the donor lung not only during EVLP but also after reperfusion.
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Figure 1
Experimental protocol using an isolated rat lung perfusion model 
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